Department of Neurosurgery, Mayo Clinic, Jacksonville, FL, 32224, USA.
Department of Neurosurgery, Mayo Clinic, Phoenix, AZ, USA.
J Neurooncol. 2022 Jan;156(2):329-339. doi: 10.1007/s11060-021-03915-3. Epub 2022 Jan 7.
Radiotherapy is considered standard of care for adjuvant peri-operative treatment of many spinal tumors, including those with instrumented fusion. Unfortunately, radiation treatment has been linked to increased risk of pseudoarthrosis. Newer focused radiotherapy strategies with enhanced conformality could offer improved fusion rates for these patients, but this has not been confirmed.
We performed a retrospective analysis of patients at three tertiary care academic institutions with primary and secondary spinal malignancies that underwent resection, instrumented fusion, and peri-operative radiotherapy. Two board certified neuro-radiologists used the Lenke fusion score to grade fusion status at 6 and 12-months after surgery. Secondary outcomes included clinical pseudoarthrosis, wound complications, the effect of radiation timing and radiobiological dose delivered, the use of photons versus protons, tumor type, tumor location, and use of autograft on fusion outcomes.
After review of 1252 spinal tumor patients, there were 60 patients with at least 6 months follow-up that were included in our analyses. Twenty-five of these patients received focused radiotherapy, 20 patients received conventional radiotherapy, and 15 patients were treated with protons. There was no significant difference between the groups for covariates such as smoking status, obesity, diabetes, intraoperative use of autograft, and use of peri-operative chemotherapy. There was a significantly higher rate of fusion for patients treated with focused radiotherapy compared to those treated with conventional radiotherapy at 6-months (64.0% versus 30.0%, Odds ratio: 4.15, p = 0.036) and 12-months (80.0% versus 42.1%, OR: 5.50, p = 0.022). There was a significantly higher rate of clinical pseudoarthrosis in the conventional radiotherapy cohort compared to patients in the focused radiotherapy cohort (19.1% versus 0%, p = 0.037). There was no difference in fusion outcomes for any of the secondary outcomes except for use of autograft. The use of intra-operative autograft was associated with an improved fusion at 12-months (66.7% versus 37.5%, OR: 3.33, p = 0.043).
Focused radiotherapy may be associated with an improved rate of fusion and clinical pseudoarthrosis when compared to conventional radiation delivery strategies in patients with spinal tumors. Use of autograft at the time of surgery may be associated with improved 12-month fusion rates. Further large-scale prospective and randomized controlled studies are needed to better stratify the effects of radiation delivery modality in these patients.
放射治疗被认为是许多脊柱肿瘤(包括接受过器械融合的脊柱肿瘤)辅助围手术期治疗的标准治疗方法。不幸的是,放射治疗已被证明与假关节形成风险增加有关。具有更好适形性的新型聚焦放射治疗策略可能会为这些患者提供更高的融合率,但这尚未得到证实。
我们对三家三级学术医疗机构的原发性和继发性脊柱恶性肿瘤患者进行了回顾性分析,这些患者接受了手术切除、器械融合和围手术期放射治疗。两名经过委员会认证的神经放射科医生使用 Lenke 融合评分在手术后 6 个月和 12 个月时对融合状态进行分级。次要结果包括临床假关节、伤口并发症、放射治疗时间和放射生物剂量的影响、光子与质子的使用、肿瘤类型、肿瘤位置以及自体移植物对融合结果的影响。
在对 1252 例脊柱肿瘤患者进行回顾性分析后,我们纳入了 60 例至少随访 6 个月的患者进行分析。这些患者中有 25 例接受了聚焦放射治疗,20 例接受了常规放射治疗,15 例接受了质子治疗。在吸烟状况、肥胖、糖尿病、术中自体移植物使用和围手术期化疗等混杂因素方面,各组之间没有显著差异。与接受常规放射治疗的患者相比,接受聚焦放射治疗的患者在 6 个月(64.0%与 30.0%,优势比:4.15,p=0.036)和 12 个月(80.0%与 42.1%,OR:5.50,p=0.022)时的融合率显著更高。与接受聚焦放射治疗的患者相比,接受常规放射治疗的患者的临床假关节发生率显著更高(19.1%与 0%,p=0.037)。除了自体移植物的使用之外,其他次要结果的融合结果没有差异。术中使用自体移植物与 12 个月时的融合改善相关(66.7%与 37.5%,OR:3.33,p=0.043)。
与常规放射治疗策略相比,聚焦放射治疗可能与脊柱肿瘤患者的融合率和临床假关节形成率提高有关。手术时使用自体移植物可能与 12 个月时的融合率提高有关。需要进一步的大规模前瞻性和随机对照研究来更好地分层这些患者的放射治疗方式的影响。